The estimated Net Worth of Thomas Gad is at least $38.2 Million dollars as of 10 June 2024. Mr. Gad owns over 70,000 units of Y-Mabs Therapeutics Inc stock worth over $2,158,777 and over the last 6 years he sold YMAB stock worth over $35,250,437. In addition, he makes $766,747 as Chairman of the Board, President, Founder, and Head of Business Development and Strategy at Y-Mabs Therapeutics Inc.
Thomas has made over 85 trades of the Y-Mabs Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 70,000 units of YMAB stock worth $841,400 on 10 June 2024.
The largest trade he's ever made was selling 281,170 units of Y-Mabs Therapeutics Inc stock on 7 February 2022 worth over $2,021,612. On average, Thomas trades about 24,335 units every 20 days since 2018. As of 10 June 2024 he still owns at least 162,681 units of Y-Mabs Therapeutics Inc stock.
You can see the complete history of Mr. Gad stock trades at the bottom of the page.
Thomas Gad is the Chairman of the Board, President, Founder, Head of Business Development and Strategy of the Company. Mr. Gad founded our Company in April 2015 and has served as our Chairman, President and Head of Business Development and as a member of our Board of Directors since our inception. Mr. Gad founded our Company inspired by his daughter, who went through six (6) years of various cancer treatments before receiving breakthrough cancer immunotherapy at MSK and overcoming high-risk neuroblastoma. He was also responsible for securing executive management and seed capital for our Company. Mr. Gad has more than 12 years of industry experience in the pharmaceutical industry, including business development, senior management, financing and licensing negotiations and manufacturing site qualification. Mr. Gad was the founder and sole owner of Y-mAbs Holding, ApS, a personal holding company involved in research and development activities in the pharmaceutical industry from 2014 until the company was placed in liquidation proceedings in 2015. The company is now under compulsory dissolution proceedings. This company is unrelated to our Company. He was the co-founder of Singad Pharma, a Danish specialty pharmaceutical and distribution company, from 2003 to 2013. Prior to that, Mr. Gad worked with Aspen Capital Partners/FFC A/S in investment banking from 1998 to 2003 and has extensive experience in raising capital for publicly listed companies. Mr. Gad has a B.S. in Business Administration from Pepperdine University.
As the Chairman of the Board, President, Founder, and Head of Business Development and Strategy of Y-Mabs Therapeutics Inc, the total compensation of Thomas Gad at Y-Mabs Therapeutics Inc is $766,747. There are 2 executives at Y-Mabs Therapeutics Inc getting paid more, with Claus Moller-San Pedro having the highest compensation of $967,497.
Thomas Gad is 50, he's been the Chairman of the Board, President, Founder, and Head of Business Development and Strategy of Y-Mabs Therapeutics Inc since . There are 10 older and 7 younger executives at Y-Mabs Therapeutics Inc. The oldest executive at Y-Mabs Therapeutics Inc is Dr. Torben Lund-Hansen, 70, who is the Sr. VP & Chief Technical Officer.
Thomas's mailing address filed with the SEC is C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, NEW YORK, NY, 10169.
Over the last 6 years, insiders at Y-Mabs Therapeutics Inc have traded over $85,284,951 worth of Y-Mabs Therapeutics Inc stock and bought 1,819,126 units worth $23,554,756 . The most active insiders traders include James Healy, Thomas Gad, and Johan Wedell Wedellsborg. On average, Y-Mabs Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $494,414. The most recent stock trade was executed by Torben Lund Hansen on 28 August 2024, trading 50,000 units of YMAB stock currently worth $219,000.
y-mabs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. the company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express gd2 and b7-h3, respectively. our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. with the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.
Y-Mabs Therapeutics Inc executives and other stock owners filed with the SEC include: